Department of Internal Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, 130 Dongdeok-ro, Jung-gu, Daegu 41944, Korea.
Department of Biochemistry and Cell Biology, Cell and Matrix Research Institute, School of Medicine, Kyungpook National University, 680 Gukchaebosang-ro, Jung-gu, Daegu 41944, Korea.
Genes (Basel). 2022 Aug 19;13(8):1484. doi: 10.3390/genes13081484.
Circular RNAs (circRNAs) are potential biomarkers owing to their stability, tissue specificity, and abundance. This study aimed to evaluate the clinical significance of hsa_circ_0003570 expression and to investigate its potential as a biomarker in hepatocellular carcinoma (HCC). We evaluated hsa_circ_0003570 expression in 121 HCC tissue samples, its association with clinicopathological characteristics, and overall and progression-free survival. Hsa_circ_0003570 expression was downregulated in HCC tissues. Low hsa_circ_0003570 expression was more common in tumors larger than 5 cm (odds ratio (OR), 6.369; 95% confidence interval (CI), 2.725−14.706; p < 0.001), vessel invasion (OR, 5.128; 95% CI, 2.288−11.494; p < 0.001); advanced tumor-node metastasis stage (III/IV; OR, 4.082; 95% CI, 1.866−8.929; p < 0.001); higher Barcelona Clinic Liver Cancer stage (B/C; OR, 3.215; 95% CI, 1.475−6.993; p = 0.003); and higher AFP (>200 ng/mL; OR, 2.475; 95% CI, 1.159−5.291; p = 0.018). High hsa_circ_0003570 expression was an independent prognostic factor for overall survival (hazard ratio (HR), 0.541; 95% confidence interval (CI), 0.327−0.894; p = 0.017) and progression-free survival (HR, 0.633; 95% CI, 0.402−0.997; p = 0.048). Hsa_circ_0003570 is a potential prognostic biomarker in patients with HCC, and further validation of hsa_circ_0003570 is needed.
环状 RNA（circRNAs）因其稳定性、组织特异性和丰度而成为有潜力的生物标志物。本研究旨在评估 hsa_circ_0003570 表达的临床意义，并探讨其作为肝细胞癌（HCC）生物标志物的潜力。我们评估了 121 例 HCC 组织样本中 hsa_circ_0003570 的表达，及其与临床病理特征以及总生存期和无进展生存期的关系。hsa_circ_0003570 在 HCC 组织中表达下调。在肿瘤大于 5cm（比值比（OR），6.369；95%置信区间（CI），2.725−14.706；p<0.001）、血管侵犯（OR，5.128；95%CI，2.288−11.494；p<0.001）、巴塞罗那临床肝癌分期（III/IV 期；OR，4.082；95%CI，1.866−8.929；p<0.001）、更高的巴塞罗那临床肝癌分期（B/C 期；OR，3.215；95%CI，1.475−6.993；p=0.003）和更高的 AFP（>200ng/mL；OR，2.475；95%CI，1.159−5.291；p=0.018）的患者中，hsa_circ_0003570 表达较低。高 hsa_circ_0003570 表达是总生存期（风险比（HR），0.541；95%CI，0.327−0.894；p=0.017）和无进展生存期（HR，0.633；95%CI，0.402−0.997；p=0.048）的独立预后因素。hsa_circ_0003570 是 HCC 患者潜在的预后生物标志物，需要进一步验证 hsa_circ_0003570 的作用。
